• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25 filed by Second Sight Medical Products Inc.

    9/8/22 5:08:15 PM ET
    $EYES
    Industrial Specialties
    Health Care
    Get the next $EYES alert in real time by email
    25 1 g083183_form25.htm 25

     

      UNITED STATES OMB APPROVAL
      SECURITIES AND EXCHANGE COMMISSION OMB Number:      3235-0080
      Washington, D. C. 20549 Expires:            May 31, 2024
        Estimated average burden
      FORM 25 hours per response                   1.00

     

     

    NOTIFICATION OF REMOVAL FROM LISTING AND/OR

    REGISTRATION UNDER SECTION 12(b) OF THE 

    SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number 001-36747    

     

    Vivani Medical, Inc.                     Nasdaq Capital Market

     

    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

     

    5858 Horton Street, Suite 280, Emeryville CA 94608 (818) 833-5000

     

    (Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

     

    Warrant 

     

    (Description of class of securities)

     

    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

     

    ☐ 17 CFR 240.12d2-2(a)(1)

     

    ☐ 17 CFR 240.12d2-2(a)(2)

     

    ☐ 17 CFR 240.12d2-2(a)(3)

     

    ☐ 17 CFR 240.12d2-2(a)(4)

     

    ☐ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange1

     

    ☒ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Vivani Medical, Inc.  (Name of Issuer or Exchange) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

     

    September 8, 2022   By Brigid Makes   CFO
    Date   Name   Title  

     

     

    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

     

    SEC 1654 (03-06) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  

     

     

     

     

    GENERAL INSTRUCTIONS

     

    1. This form is required by Rule 12d2-2 (17 CFR 240.12d2-2) of the General Rules and Regulations under the Securities Exchange Act of 1934 (“Exchange Act”).

     

    2. Exchanges: Attach the delisting determination to this Form 25 to serve as the required Notice pursuant to Exchange Act Rule 19d-1 (17 CFR 240.19d-1). Form 25 and the attached Notice will be considered compliance with the provisions of Rule 19d-1 as applicable.

     

    3. The Form 25 and any attachments must be filed electronically on the EDGAR database.

     

    4. The removal of the class of securities from listing on the exchange shall be effective 10 days after filing the Form 25. With respect to the filing of any amendment to Form 25, the removal of the class of securities from listing on the exchange shall be effective 10 days after filing the amended Form 25.

     

    5. The withdrawal of registration of a class of securities registered under Section 12(b) of the Exchange Act shall take effect in 90 days, or such shorter period as the Commission may determine, after the exchange or issuer files a Form 25 with the Commission. With respect to the filing of any amendment to Form 25, the withdrawal of registration of a class of securities registered under Section 12(b) shall take effect in 90 days, or such shorter period as the Commission may determine, after the exchange or issuer files the amended Form 25.

     

    6. For purposes of Section 12 of the Exchange Act, a class of securities shall no longer be considered listed on a national securities exchange upon the effective date of delisting even though the withdrawal of registration is effective at a later time.

     

    7. The issuer’s duty to file any reports under Section 13(a) of the Exchange Act and the rules and regulations thereunder as are result of the security’s registration under Section 12(b) of the Exchange Act shall be suspended upon the effective date of the delisting. If, following the effective date of delisting, the withdrawal of registration under Section 12(b) is delayed by the Commission, an exchange, or an issuer, the issuer shall, within 60 days of such delay, file any reports that would have been required under Section 13(a) and the rules and regulations thereunder, had the Form 25 not been filed. The issuer will also file any subsequent reports required under Section 13(a) for the duration of the delay.

     

    8. An issuer whose reporting responsibilities under Section 13(a) of the Exchange Act are suspended for a class of securities under Rule 12d2-2(d)(5) is, nevertheless, required to file any reports that an issuer with such a class of securities registered under Section 12 of the Exchange Act would be required to file under Section 13(a) if such class of securities: 

    (a) is registered under Section 12(g) of the Exchange Act; or 

    (b) would be registered, or would be required to be registered, under Section 12(g) of the Exchange Act but for the exemption from registration under Section 12(g) provided by Section 12(g)(2)(A) of the Exchange Act.

     

    9. An issuer whose reporting responsibilities under Section 13(a) of the Exchange Act are suspended under Rule 12d2-2(d)(5) is, nevertheless, required to file any reports that would be required under Section 15(d) of the Exchange Act but for the fact that the reporting obligations are: (a) suspended for a class of securities under Rule 12d2-2(d)(5); and (b) suspended, terminated, or otherwise absent under Section 12(g) of the Exchange Act. The reporting responsibilities of an issuer under Section 15(d) of the Exchange Act shall continue until the issuer is required to file reports under Section 13(a) of the Exchange Act or the issuer’s reporting responsibilities under Section 15(d) are otherwise suspended.

     

    10. Issuers should determine if they have additional registration and reporting requirements under Section 12(g) of the Exchange Act and reporting obligations pursuant to Section 15(d) of the Exchange Act upon the filing of Form 25.

     

    11. In any case where the Commission has commenced a proceeding under Section 12 of the Exchange Act prior to the withdrawal of the registration of a class of securities becoming effective, such security will remain registered under Section 12(b) of the Exchange Act until the final decision of such proceeding, or until the Commission otherwise determines to suspend the effective date of, or revoke, the registration of a class of securities.

     

    12. In the event removal is being effected under Rule 12d2-2(a)(3) and the national securities exchange has admitted or intend so admit a successor security to trading under the temporary exemption provided for by Exchange Act Rule 12a-5 (17 CFR 240.12a-5) there For 25 shall be filed with the Commission in a manner that ensures that the delisting does not become effective until the successor security is removed from its exempt status.

     

     

     

    Get the next $EYES alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EYES
    SEC Filings

    See more
    • Second Sight Medical Products Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      1/6/23 4:04:18 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      12/15/22 4:45:35 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Vivani Medical, Inc. (0001266806) (Filer)

      11/28/22 5:29:22 PM ET
      $EYES
      Industrial Specialties
      Health Care

    $EYES
    Financials

    Live finance-specific insights

    See more
    • Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company

      Nano Precision Medical's lead program (NPM-119) is a tiny subdermal implant of a GLP-1 receptor agonist to treat patients with Type 2 diabetes Second Sight will issue 134M shares to acquire full ownership of Nano Precision Medical. Second Sight shareholders will own ~23% of the combined company. Second Sight shareholders join NPM shareholders, including AstraZeneca which has been a strategic investor since 2016 Second Sight currently has over $69M to enable the advancement of NPM-119 through clinical proof of concept into a pivotal clinical trial and continued exploration of the visual prosthesis business opportunity Investor Conference Call Scheduled for Tuesday, February 8, 2022,

      2/7/22 4:30:00 PM ET
      $EYES
      Industrial Specialties
      Health Care

    $EYES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EYES
    Leadership Updates

    Live Leadership Updates

    See more

    $EYES
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 4 filed by Mendelsohn Adam

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      1/23/23 9:13:06 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Makes Brigid

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      1/23/23 9:11:40 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Dwyer Donald

      4 - Vivani Medical, Inc. (0001266806) (Issuer)

      1/23/23 9:09:48 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

      Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat

      7/29/22 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products Announces Results of its 2021 Annual Meeting

      Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held May 28, 2021. Second Sight held its annual meeting online due to the COVID-19 pandemic. 60.98% of shareholders were present online or by proxy. Shareholders voted on four proposals: (1) electing six (6) members of the Board of Directors, to serve until the next annual meeting of shareholders in 2022 and until their successors are duly elected and qualified, (2) ratifying the appointment of Gumbiner Savett Inc. as our

      6/1/21 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market

      Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market Aims to create a global leader with potential to treat nearly all forms of blindnessCombined company to trade on Nasdaq and benefit from business and development synergies in the U.S. and EuropeTransaction provides broader access to financing sources to enable the combined company to accelerate the development and commercialization of its productsPixium Vision to remain listed on Euronext Growth and to be the largest shareholder of the new combined company listed on NasdaqTransaction expected to close in late Q1 or the beginning of Q2 2021Conference Call s

      1/6/21 12:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)

      Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ:VANI) (the "Company" or "Vivani") announced that trading of the Company's common stock on The Nasdaq Capital Market under the symbol "VANI" will commence today. Vivani is the combination of Nano Precision Medical, Inc. ("NPM") and Second Sight Medical Products, Inc. Closing of the merger was completed and announced yesterday, August 30, 2022. Vivani leverages proprietary technologies to develop and commercialize drug and device implants that treat patients with chronic diseases with high unmet medical need. Vivani has approximately $55 million in cash to advance the development of its portfolio, which includes lead asset N

      8/31/22 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

      Vivani will be traded under the new ticker (NASDAQ:VANI) Second Sight Medical Products, Inc.(NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced today the completion of its merger with Nano Precision Medical, Inc. ("NPM"). NPM is a biopharmaceutical business which develops miniaturized, subdermal drug implants utilizing its proprietary NanoPortal™ technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. In connection with the merger, Second Sight changed its name to Vivani Medical, Inc

      8/30/22 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care
    • Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

      Second Sight to change its name to Vivani Medical, Inc. Second Sight Medical Products, Inc. (NASDAQ:EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced results of its annual meeting held on July 27, 2022, where the quorum was present. The formal results of the vote are included in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission. At the annual meeting, the shareholders voted on seven proposals: (1) approving the merger agreement with Nano Precision Medical, Inc. ("NPM") and the transactions contemplat

      7/29/22 6:00:00 AM ET
      $EYES
      Industrial Specialties
      Health Care

    $EYES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Second Sight Medical Products Inc. (Amendment)

      SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

      9/1/22 9:34:58 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by Second Sight Medical Products Inc.

      SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

      8/31/22 6:49:04 PM ET
      $EYES
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Second Sight Medical Products Inc. (Amendment)

      SC 13D/A - SECOND SIGHT MEDICAL PRODUCTS INC (0001266806) (Subject)

      7/22/22 5:06:56 PM ET
      $EYES
      Industrial Specialties
      Health Care